Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — Investor Presentation (March 2021)
19 slides from Stablecoin Development's investor presentation, March 2021
Slide 1: Investor Presentation March 2021
Investor Presentation March 2021 NYSE American: NBY www.Novabay.com www.Avenova.com www.Cellerx.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
Slide 3: NovaBay Overview
NovaBay Overview • Established Avenova® as the No. 1 antimicrobial lid and lash spray in the U.S. dry eye market • Multi-pronged commercial distribution strategy • 20mL available direct-to-consumer without a prescription • Online channels like Amazon.com, Walmart.com, CVS.com, and Avenova.com • Near
Slide 4: Investment Highlights
Investment Highlights • Consumer launch in 4Q‘20 of CelleRx Clinical Reset, allowing NovaBay to enter the large beauty market • Avenova is established in the $4 billion U.S. dry eye market with differentiated positioning and multiple product-specific features and benefits • Avenova is the only comme
Slide 5: Patented HOCI Formulation is a Platform Technology
Patented HOCI Formulation is a Platform Technology AVENOVA AND CELLERX ARE ALL FORMULATED WITH NOVABAY’S PURE HOCI, WHICH IS FDA 510(K) CLEARED Natural molecule is part of the body’s innate immune system • Effective against all types of pathogens, including a wide variety of viruses such as coronavi
Slide 6: CelleRx Clinical Reset
CelleRx Clinical Reset INPROCESS Launched 4Q’20 Direct-to-Consumer Into High-end Beauty Market 6
Slide 7: CelleRx Clinical Reset | A New Category in Beauty Products
CelleRx Clinical Reset | A New Category in Beauty Products • FDA-cleared skincare product proven to help clean and reduce bacteria buildup on facial skin • Complementary to a daily beauty regimen • Allows other skincare products to work better • Resets natural microbiome – when out of balance can al
Slide 8: CelleRx Clinical Reset – social media marketing
CelleRx Clinical Reset – social media marketing INPROCESS @CELLERXSKIN SOCIAL MEDIA PRESENCE FOR BEAUTY AND SKIN MARKET DAILY POSTING AND STORIES LIFESTYLE IMAGES AND CONTENT PRESCRIPTION GRADE SKINCARE 8
Slide 9: CelleRx Clinical Reset Consumer Strategy
CelleRx Clinical Reset Consumer Strategy • Leveraging new consumer-focused messaging and NovaBay’s pharmaceutical pedigree in robust social media and print advertising campaigns marketing in the beauty industry • Debuting in the traditional beauty press and with early access for leading beauty indus
Slide 10: Avenova Market Opportunity
Avenova Market Opportunity U.S. POPULATION WITH EYE BACTERIA CONCERNS Bacterial Dry Eye is the Most Common Form • Bacterial dry eye (meibomian gland dysfunction and blepharitis) represents 86% of dry eye patients 11 Million • Aqueous deficient dry eye, treated by Restasis® and Xiidra® represent ONLY
Slide 11: Avenova Advantages
Avenova Advantages • Clinical study confirms Avenova’s ability to reduce bacteria on ocular surface by >90%, not merely treat the symptoms • Kills >20 microorganisms connected to common eye infections within seconds; effective against a range of pathogens including Staphylococcus • Stable formulatio
Slide 12: Direct-to-Consumer Strategy
Direct-to-Consumer Strategy • Accounts for approximately half of Avenova revenue • Provides easy access to Avenova without a prescription or leaving home, critical during the pandemic • Helps to offset the impact of high-deductible healthcare plans • Provides NovaBay with stable gross-to-net pricing
Slide 13: Refreshed Consumer Lifestyle Branding
Refreshed Consumer Lifestyle Branding @avenvaeyecare 13
Slide 14: Avenova Prescription Sales Channels
Avenova Prescription Sales Channels • Rx Sales/Prescription Channel • Field sales, inside sales and business development Retail representatives are focused on underserved territories with high- prescribing ophthalmologists and favorable health plan coverage Pharmacies • Avenova is available in virtu
Slide 15: KOL Advisory Boards Provide Third-Party Credibility
KOL Advisory Boards Provide Third-Party Credibility • Advisory boards of industry leaders comprised of 10 ophthalmologists and 10 optometrists • Creates “doctor recommended” halo effect • Provide valuable insight into doctor perspectives on Avenova and the market • Assist in developing strategic mes
Slide 16: Leadership
Leadership • Extensive knowledge of NovaBay, having joined in 2013 and serving as CEO since 2019 JUSTIN M. HALL, ESQ • Lead successful restructuring, implemented direct-to-consumer strategy and leading consumer launch of CelleRx CEO, General Counsel & Director • Extensive legal background on wide ra
Slide 17: Strategy for Future Growth
Strategy for Future Growth • Driving Avenova and CelleRx Clinical Reset sales to consumers • DTC channel presents the greatest opportunity for growth • Enhanced e-commerce, digital marketing and advertising programs, and refreshed branding • Expanded online access and new brick-and-mortar availabili
Slide 18: Financial and Operating Highlights
Financial and Operating Highlights • Highlights of 3Q20 (2020 10-K to be filed March 25, 2021) • Revenue of $2.2 million, increase 34% over prior year • Avenova unit sales set quarterly record • Strong balance sheet to support current and future growth initiatives • $13.4 million in cash and equival
Slide 19: In Summary
In Summary • Recent consumer launch of CelleRx Clinical Reset, allowing NovaBay to enter the large beauty market • Avenova is established in the $4 billion U.S. dry eye market with differentiated positioning and multiple product-specific features and benefits • Avenova is the only commercial HOCI sp
NovaBay Pharmaceuticals — Investor Presentation (March 2021) on 6ix